loading page

Exhaled 15-HETE and thromboxin-B2 are associated with the therapeutic outcome in childhood asthma
  • +12
  • Li-Chen Chen,
  • Hsu-Min Tseng,
  • Ming-Ling Kuo,
  • Chih-Yung Chiu,
  • Sui-Ling Liao,
  • Kuan-Wen Su,
  • Ming-Han Tsai,
  • Man Chin Hua,
  • Shen-Hao Lai,
  • Tsung-Chieh Yao,
  • Kuo-Wei Yeh,
  • Ai-Hsuan Wu,
  • Hsiu-Yueh Yu,
  • Jing-Long Huang,
  • Shau-Ku Huang
Li-Chen Chen
New Taipei City Municipal Tucheng Hospital

Corresponding Author:[email protected]

Author Profile
Hsu-Min Tseng
Chang Gung University
Author Profile
Ming-Ling Kuo
New Taipei City Municipal Tucheng Hospital
Author Profile
Chih-Yung Chiu
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Sui-Ling Liao
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Kuan-Wen Su
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Ming-Han Tsai
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Man Chin Hua
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Shen-Hao Lai
Chang Gung Memorial Hospital Keelung Branch Library
Author Profile
Tsung-Chieh Yao
Chang Gung Memorial Hospital Linkou Main Branch
Author Profile
Kuo-Wei Yeh
Chang Gung Memorial Hospital Linkou Main Branch
Author Profile
Ai-Hsuan Wu
New Taipei City Municipal Tucheng Hospital
Author Profile
Hsiu-Yueh Yu
New Taipei City Municipal Tucheng Hospital
Author Profile
Jing-Long Huang
New Taipei City Municipal Tucheng Hospital
Author Profile
Shau-Ku Huang
National Health Research Institutes
Author Profile

Abstract

Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled LTB4, characterizes childhood asthma. While FeNO has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB4, the levels of exhaled 15-HETE, but not TXB2, showed significant difference between asthmatics (N=318) and healthy controls (N=97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver Operating Characteristic (ROC) analyses revealed similar distinguishing power for the levels of 15-HETE, FEV1 and FeNO, whilethe 15-HETE/LTB4 ratio was significantly lower in subjects with severe asthma (p<0.01). Analysis of asthmatics (N=75) during exacerbation and convalescence showed significant improvement in lung function (FEV1; p<0.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p<0.001) and reduced levels of TXB2 (p<0.05) after therapy, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB4 and LXA4 at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB2 and increased levels of 15-HETE were prominent after treatment.
01 Apr 2021Submitted to Pediatric Allergy and Immunology
01 Apr 2021Reviewer(s) Assigned
16 Apr 2021Review(s) Completed, Editorial Evaluation Pending
28 Apr 2021Editorial Decision: Revise Major
04 Jun 20211st Revision Received
18 Jun 2021Review(s) Completed, Editorial Evaluation Pending
18 Jun 2021Editorial Decision: Accept